Alumis (ALMS) Other Non Operating Income (2023 - 2026)
Alumis (ALMS) posted quarterly Other Non Operating Income of -$183.3 million for Q4 2025, down 2191.83% year-over-year from $8.8 million in Q4 2024, and down 339318.52% quarter-over-quarter from -$54000.0 in Q3 2025.
Alumis (ALMS) Other Non Operating Income (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Other Non Operating Income for 3 consecutive years, with -$183.3 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non Operating Income fell 2191.83% year-over-year to -$183.3 million; the TTM figure through Dec 2025 stood at $4.5 million (down 47.85% YoY), while the FY2025 annual figure was $4.6 million, up 37.69% from the prior year.
- Other Non Operating Income declined to -$183.3 million in Q4 2025 per ALMS's latest filing, from -$54000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $187.9 million in Q2 2025 and bottomed at -$183.3 million in Q4 2025.
- Historically, Other Non Operating Income has averaged $1.3 million across 3 years, with a median of -$26000.0 in 2023.
- On a YoY basis, Other Non Operating Income climbed as much as 552767.65% in 2025 and fell as far as 2191.83% in 2025.
- Alumis' Other Non Operating Income stood at -$18000.0 in 2023, then soared by 48777.78% to $8.8 million in 2024, then slumped by 2191.83% to -$183.3 million in 2025.
- Business Quant data shows ALMS's Other Non Operating Income at -$183.3 million in Q4 2025, -$54000.0 in Q3 2025, and $187.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Alumis | 3.25 Bn | 2.75 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -71,000.00 |
| Dec 31, 2025 | -183.29 Mn |
| Sep 30, 2025 | -54,000.00 |
| Jun 30, 2025 | 187.91 Mn |
| Mar 31, 2025 | -44,000.00 |
| Dec 31, 2024 | 8.76 Mn |
| Sep 30, 2024 | -40,000.00 |
| Jun 30, 2024 | -34,000.00 |
| Mar 31, 2024 | -15,000.00 |
| Sep 30, 2023 | -18,000.00 |
| Jun 30, 2023 | -11,000.00 |